Holen Sie sich die Stockscreener-App
1.69
1.20%
0.02
Handel nachbörslich:
1.69
In 8 Bio Inc Aktie (INAB) Neueste Nachrichten
Passage Bio, Inc. 2026 Annual Meeting Results: Stockholder Votes and Key Corporate Information (Form 8-K) - Minichart
Passage Bio (NASDAQ: PASG) holders choose annual say-on-pay at 2026 meeting - Stock Titan
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
VBIO SEC FilingsValion Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Annovis Bio (NYSE: ANVS) prices $15M common stock and warrant offering - Stock Titan
Exclusive Tokyo BCG supply deal expands ImmunityBio (NASDAQ: IBRX) options - Stock Titan
Debt exchange and FDA path shape Gossamer Bio (NASDAQ: GOSS) - Stock Titan
Annovis Bio (NYSE: ANVS) ramps R&D as Phase 3 Alzheimer’s trial advances - Stock Titan
Cormorant Funds disclose 10.5M-share position in Cabaletta Bio (CABA) - Stock Titan
Instil Bio, Inc. Reports First Quarter 2026 Financial Results – 8-K Filing Details and Key Highlights - Minichart
[SCHEDULE 13G/A] Adicet Bio, Inc. Amended Passive Investment Disclosure - Stock Titan
Instil Bio (Nasdaq: TIL) trims Q1 2026 loss and extends cash runway beyond 2027 - Stock Titan
Gossamer Bio, Inc.Common Stock (NQ: GOSS - FinancialContent
Valion Bio (VBIO) widens Q1 2026 loss as it builds TLR5 and CDMO platform - Stock Titan
INmune Bio (NASDAQ: INMB) wins FDA Fast Track status for XPro in early Alzheimer’s disease - Stock Titan
IPF Phase 2a results and cash runway update for GRI Bio (NASDAQ: GRI) - Stock Titan
Cabaletta Bio (NASDAQ: CABA) details Q1 loss and $150M financing - Stock Titan
Cabaletta Bio (NASDAQ: CABA) unveils new rese-cel autoimmune and PC-free data - Stock Titan
Adicet Bio (Nasdaq: ACET) trims Q1 loss and details prula-cel, ADI-212 plans - Stock Titan
Palisade Bio (NASDAQ: PALI) boosts R&D spend to advance PALI-2108 - Stock Titan
TELA Bio (NASDAQ: TELA) Q1 2026 revenue rises 3% to $19.1M - Stock Titan
TELA Bio rolls out fully resorbable hernia repair after $19M Q1 - Stock Titan
Kyntra Bio (NASDAQ: FGEN) Q1 2026 results, oncology pipeline and cash runway - Stock Titan
Avai Bio (NASDAQ: AVAI) and Ainnova mutually end AI healthcare joint venture - Stock Titan
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar
QTTB SEC FilingsQ32 BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
Boundless Bio (Nasdaq: BOLD) Q1 2026 results and $92.8M cash runway - Stock Titan
Kala Bio (NASDAQ: KALA) sets 1-for-50 reverse stock split, May 11 start - Stock Titan
LeonaBio (NASDAQ: ATHA) widens Q1 loss while funding late-stage trials - Stock Titan
BLTE SEC FilingsBelite Bio, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ImmunityBio (NASDAQ: IBRX) boosts Q1 sales but records $632.8M loss - Stock Titan
[8-K] Climb Bio, Inc. Reports Material Event - Stock Titan
Korro Bio (Nasdaq: KRRO) boosts cash to $157M and targets 2026 KRRO-121 filing - Stock Titan
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences - GlobeNewswire Inc.
INmune Bio (NASDAQ: INMB) deepens Anthony Nolan CORDStrom supply pact - Stock Titan
Climb Bio (CLYM) outlines budoprutug CD19 data, 2026 trial readouts and cash runway - Stock Titan
Q32 Bio (QTTB) narrows Q1 2026 loss and funds runway into 1H 2028 - Stock Titan
Valion Bio (Nasdaq: VBIO) hires Melinda Lackey as General Counsel - Stock Titan
Cabaletta Bio, Inc. Files Form 8-K with SEC – Company Information, Stock Details, and Compliance Disclosure - Minichart
Cabaletta Bio (NASDAQ: CABA) prices $150M equity raise to fund rese-cel - Stock Titan
Cabaletta Bio (NASDAQ: CABA) to share new rese-cel RESET-PV data at ASGCT 2026 - Stock Titan
ACET SEC FilingsAdicet Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
[ARS] TELA Bio, Inc. SEC Filing - Stock Titan
Leadership shake-up at TELA Bio (NASDAQ: TELA) as new chair named - Stock Titan
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th - The Manila Times
Valion Bio, Inc. Common Stock (VBIO) 10K Form and Latest SEC Filings 2026 - MarketBeat
[ARS] Boundless Bio, Inc. SEC Filing - Stock Titan
Adicet Bio (NASDAQ: ACET) issues 250,000-share pre-funded warrant in exchange deal - Stock Titan
Climb Bio (CLYM) secures $110M private placement with institutional investors - Stock Titan
Passage Bio (NASDAQ: PASG) slashes workforce by 75% in 2026 restructuring - Stock Titan
BIO-key International, Inc. Files 8-K Report on Security Holder Vote Results – April 2026 - Minichart
Shareholders of Bio-Rad (NYSE: BIO) approve 2017 incentive plan changes - Stock Titan
[ARS] Instil Bio, Inc. SEC Filing - Stock Titan
BIO-key (NASDAQ: BKYI) wins approval for flexible reverse stock split - Stock Titan
[ARS] Gossamer Bio, Inc. SEC Filing - Stock Titan
Q32 Bio (NASDAQ: QTTB) adds $75M ATM common stock capacity - Stock Titan
Valion Bio (Nasdaq: TIVC) pivots to late-stage biopharma with Entolimod and CDMO - Stock Titan
Tevogen Bio (NASDAQ: TVGN) warned on Nasdaq $50M, $15M value tests - Stock Titan
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):